Skip to main content

Advertisement

Log in

Psychosocial aspects in myasthenic patients treated by plasmapheresis

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Knowledge about the postintervention psychosocial status of myasthenia gravis (MG) is limited and based on questionnaire studies. In this study, the effects of improvement in muscle strength with plasmapheresis treatment on both quality of life (QoL) and psychological status of MG patients were studied. Between January 2008 and December 2009, 29 MG patients were enrolled to receive one course of plasmapheresis treatment. Differences in baseline and posttherapy clinical, laboratory, and psychosocial measures were determined. The mean MG score decreased from 7.8 points at baseline to 4.2 after plasmapheresis, accompanied by the mean antibody clearance of 56%. Psychosocial tests showed significant pre- and posttherapy differences in illness identity (mean scores 23.62 and 20.79 points, respectively) and disability (mean scores 11.28 and 7.63 points, respectively) (p < 0.01). No significant differences were found for the other indices. Although both anxiety and depression scores did not differ significantly, there was a clear change in patients, as evidenced by their decreases in severity after treatment. The mean mental components scores of QoL were still less than 40 after treatment, indicating that myasthenic patients need assistance in adapting to their disease. Thus, although plasmapheresis treatment achieved immediate improvement of myasthenic symptoms, reduced disability, and better illness identity, both emotional status and QoL did not differ significantly after intervention. Systematical evaluation for patients’ illness perceptions and emotional problems are warranted and related strategies should be taken for long-term stabilization of psychosocial function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Burns TM, Conaway MR, Cutter GR, Sanders DB (2008) Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 38:957–963

    Article  PubMed  Google Scholar 

  2. Busch C, Machens A, Pichlmeier U (1996) Long-term outcomes and quality of life after thymectomy for myasthenia gravis. Ann Surg 2:225–232

    Article  Google Scholar 

  3. Chaudhuri A, Behan PO (2009) Myasthenic crisis. QJ Med 102:97–107

    CAS  Google Scholar 

  4. Chen YT, Tsay SL, Lin PF (2003) The relationships between illness perception, mood and quality of life in myasthenia gravis patients. J Nurs 50:43–50 (in Chinese)

    Google Scholar 

  5. Doering S, Henze T, Schüssler G (1993) Coping with myasthenia gravis and implications for psychotherapy. Arch Neurol 50:617–620

    PubMed  CAS  Google Scholar 

  6. García-Carrasco M, Escárcega RO, Fuentes-Alexandro S, Riebeling C, Cervera R (2007) Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev 6:373–378

    Article  PubMed  Google Scholar 

  7. Jønsson A, Dock J, Ravnborg MH (1996) Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis. Acta Neurol Scand 93:229–235

    Article  PubMed  Google Scholar 

  8. Klauer T, Schneider W, Zettl UK (2007) Coping with neuroimmunological diseases. J Neurol 254(Suppl 2):II107–II111

    Article  PubMed  Google Scholar 

  9. Lankhorst GJ, Jelles F, Smits RC, Polman CH, Kuik DJ, Pfennings LE, Cohen L, van der Ploeg HM, Ketelaer P, Vleugels L (1996) Quality of life in multiple sclerosis: the disability and impact profile. J Neurol 243:469–674

    Article  PubMed  CAS  Google Scholar 

  10. Lundeen J, Fisher J, Kothari MJ (2004) Frequency of anxiety in myasthenia gravis. J Clin Neuromuscul Dis 6:9–12

    Article  PubMed  Google Scholar 

  11. Maniaol AH, Brunborg C, Tallaksen CME (2010) Development and validation of a self-administered questionnaire for myasthenia gravis patients. Neuroepidemiology 34:253–261

    Article  PubMed  CAS  Google Scholar 

  12. Murphy N, Confavreux C, Haas J, Konig N, Roullet E, Sailer M, Young C, Merot JL (1998) Quality of life in multiple sclerosis in France, Germany, and United Kingdom. J Neurol Neurosurg Psychiatry 65:460–466

    Article  PubMed  CAS  Google Scholar 

  13. Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, Tonali P (2001) Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 22:363–369

    Article  PubMed  CAS  Google Scholar 

  14. Paul RH, Cohen RA, Goldstein JM, Gilchrist JM (2000) Fatigue and its impact on patients with myasthenia gravis. Muscle Nerve 23:1402–1406

    Article  PubMed  CAS  Google Scholar 

  15. Paul RH, Cohen RD, Goldstein JM, Gilchrist JM (2000) Severity of mood, self-evaluation, and vegetative symptoms of depression in myasthenia gravis. Neuropsychiatry Clin Neurosci 12:499–501

    Article  CAS  Google Scholar 

  16. Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM (2001) Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 24:512–515

    Article  PubMed  CAS  Google Scholar 

  17. Phillip LH II, Torner JC (1996) Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 47:1233–1238

    Google Scholar 

  18. Pinching AJ, Peters DK, Newsom-Davis J (1976) Remission of myasthenia gravis following plasma-exchange. Lancet II:1373–1376

    Article  Google Scholar 

  19. Sanders DB, Hart IK, Mantegazza R et al (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400–406

    Article  PubMed  CAS  Google Scholar 

  20. Sitek EJ, Bilińska MM, Wieczorek D, Nyka WM (2009) Neuropsychological assessment in myasthenia gravis. Neurol Sci 30:9–14

    Article  PubMed  Google Scholar 

  21. Thomas CE, Mayer SA, Gungor Y et al (1997) Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48:1253–1260

    PubMed  CAS  Google Scholar 

  22. Van der Schaaf IC, Brilstra EH, Rinkel GJE, Bossuyt PM, van Gijn J (2002) Quality of life, anxiety, and depression in patients with an intracranial aneurysm or arterio-venous malformation. Stroke 33:440–443

    Article  PubMed  Google Scholar 

  23. Wolinsky FD, Stump TE (1996) A measurement model of the Medical Outcomes Study 36-Item Short-Form Health Survey in a clinical sample of disadvantaged, older, black, and white men and women. Med Care 34:537–548

    Article  PubMed  CAS  Google Scholar 

  24. Yeh JH, Chen WH, Chiu HC (2001) Double filtration plasmapheresis in the treatment of myasthenic crisis–analysis of prognostic factors and efficacy. Acta Neurol Scand 104:78–82

    Article  PubMed  CAS  Google Scholar 

  25. Yeh JH, Chiu HC (1999) Double filtration plasmapheresis in myasthenia gravis-analysis of clinical efficacy and prognostic parameters. Acta Neurol Scand 100:305–309

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported, in part, by research grants (SKH-8302-97-DR-17) from the Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jiann-Horng Yeh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, YT., Chang, Y., Chiu, HC. et al. Psychosocial aspects in myasthenic patients treated by plasmapheresis. J Neurol 258, 1240–1246 (2011). https://doi.org/10.1007/s00415-011-5913-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-011-5913-4

Keywords

Navigation